|
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
Jul 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
Jul 2024 |
Blood |
Aplastic Anemia |
|
Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis |
Jul 2024 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
Jul 2024 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications |
Jul 2024 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency |
Jul 2024 |
Blood Transfusion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes |
Jun 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Kidney involvement in myelodysplastic syndromes |
Jun 2024 |
Clinical Kidney Journal |
Myelodysplastic Syndromes (MDS) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Jun 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
